Hematopoietic SCT in Europe: data and trends in 2011

Abstract

In all, 651 from 680 centers in 48 countries reported 35 660 hematopoietic SCT (HSCT) in 32 075 patients (13 470 allogeneic (42%), 18 605 autologous (58%)) to the 2011 survey. Main indications were: leukemias; 10 113 (32%; 94% allogeneic); lymphoid neoplasias; non-Hodgkin's lymphoma, Hodgkin's lymphoma, plasma cell disorders; 18 433 (57%; 12% allogeneic); solid tumours; 1573 (5%; 5% allogeneic); and non-malignant disorders; 1830 (6%; 92% allogeneic). There were more unrelated donors than HLA identical sibling donors (54% versus 39%); proportion of peripheral blood as stem cell source was 99% for autologous and 73% for allogeneic HSCT. Cord blood was only used in allogeneic transplants (6% of total). In the past 10 years, the overall number of transplants has increased by 53%. Allogeneic HSCT have doubled (from 7272 to 14 549) while, autologous have increased by 32% and continue to increase by about 1100 HSCT per year since 2001. In the past 2 years, an increase of >2000 HSCT per year was seen. Transplant activity is shown by team size. For allogeneic HSCT, we show use of reduced-intensity conditioning versus myeloablative conditioning across Europe and use of post-transplant donor lymphocyte infusions with considerable variation across different countries.

Figure 1

Absolute numbers and relative proportions of indications for an HSCT in Europe in 2011. (a) Proportions of disease indications for an allogeneic HSCT in Europe in 2011. (b) Proportions of disease indications for an autologous HSCT in Europe in 2011. BMF=bone marrow failure; HD= Hodgkin's disease; IDM=inherited disorders of metabolism; MDS=myelodysplastic syndrome; MPS=myeloproliferative syndrome; NHL=non-Hodgkin's lymphoma; PCD=plasma cell disroder; PID=primary immunodeficiency.

Figure 2

Donor type and stem cell source in allogeneic HSCT. (a) Stem cell source in allogeneic HSCT in 2011. (b) Donor type in allogeneic HSCT in 2011. CB=cord blood.

Figure 3

RIC in allogeneic HSCT. (a) Absolute numbers of RIC HSCT 2000–2011. (b) Percentage of patients receiving RIC HSCT during the years 2007–2011 in countries performing >100 allogeneic HSCT per year.

Figure 4

DLI in allogeneic HSCT. (a) Absolute numbers of patients receiving DLI since 1997. (b) Percentage of patients receiving DLI during the years 2007–2011 in countries performing >100 allogeneic HSCT per year.

Figure 5

Transplant rates in Europe (=total number of HSCT per 10 million inhabitants) by participating country. (a) Allogeneic transplant rates per10 million population in 2011. (b) Autologous transplant rates per 10 million population in 2011.